Stock Watch 03 August 2010

The Share Centre’s top 5 customer buys from the last 7 days

1. BP – Buying ahead of the new cap being fitted at the end of last week.
2. Connaught – Investors taking a brave gamble as to the survival of the company.
3. Lloyds Banking Group – Investors buying ahead results being issued week commencing 2 August.
4. Glaxo – Investors buying after recent weakness.
5. Barclays – Investors buying ahead results being issued week commencing 2 August.



The Share Centre’s top 5 shares to follow:

1. Reckitt Benckiser Lower Risk – Looking to aggressively expand the company, latest purchase being SSL International.
2. Compass Lower Risk – Trading update in-line worth adding to a portfolio.
3. Croda International Medium Risk – Results impressed and shares still look attractive.
4. International Power Medium Risk – Collaborations with the French could be on the cards.
5. Bowleven Higher Risk – Oil company with plenty of potential.


Ratio of buys to sells = 57:43


Top 5 most searched for companies on www.share.com


1. Trifast
2. Opsec securities
3. Royal Bank of Scotland
4. Banco Santander
5. DSG International


The Share Centre’s Share of the Week
Company:
Hutchison China Meditech     Share price:
360.00p    Sector:
Health Care equipment
Recommendation:    Buy
Risk category:    High
Investment class:    Growth
Opinion:
Interim results reported narrower losses for the first six months of 2010 due to strong sales of its heart pills in China and organic foods in Hong Kong.

There is a rising level of affluence in China and the Government is committed to expanding its healthcare provision. Late stage trials of its experimental treatment for ulcerative colitis are due later this year or early 2011. This is good news for investors.

During the fourth quarter of this year the company is hoping to start selling organic baby food in China and this will give a significant boost to sales. This may also help the company move into profitability in the near future.

This is still a high risk play for investors we feel at the moment but as the company grows and more drugs come to market we could be looking to change that stance. We still have a buy recommendation on the stock.


Please note that Hutchison China MediTech trades on AIM and can not therefore be held in an ISA.



THIS DATA IS PROVIDED BY NICK RAYNOR, INVESTMENT ADVISER AT THE SHARE CENTRE. THIS IS NOT INTENDED TO CONSTITUTE AN OFFER OR AGREEMENT TO BUY OR SELL INVESTMENTS.
 

Moneyextra.com recommends you take independent financial advice before acting on any article

2010-08-04 12:58:23 © Moneyextra.com